Tags

Type your tag names separated by a space and hit enter

Activity of rituximab plus cyclophosphamide, doxorubicin/mitoxantrone, vincristine and prednisone in patients with relapsed MALT lymphoma.
Oncology. 2006; 70(6):411-7.O

Abstract

BACKGROUND

Various chemotherapeutic agents as well as the anti-CD20 antibody rituximab (R) have been tested in patients with mucosa-associated lymphoid tissue (MALT) lymphoma, but no standard chemotherapeutic regimen has emerged so far. Judging from the data obtained in various types of lymphoma, the activity of R appears to be enhanced by combination with chemotherapy. As no data on this topic exist for MALT lymphoma, we have retrospectively analysed our experience with R plus cyclophosphamide, doxorubicin/mitoxantrone, vincristine and prednisone (R-CHOP/R-CNOP) in patients with relapsed MALT lymphoma.

PATIENTS AND METHODS

A total of 26 patients were identified, 15 were administered R-CHOP while 11 patients were given R-CNOP due to age >65 years or pre-existing cardiac conditions. Cycles were repeated every 21 days, and restaging was performed after 4 cycles of therapy. In case of complete remission, 2 further cycles were administered for consolidation while patients achieving partial remission or stable disease after restaging were given 4 further courses.

RESULTS

A total of 170 cycles were administered to our patients (median 6, range 2-8). Twenty of the 26 patients (77%) achieved a complete remission and 6 (23%) a partial remission. Toxicities were mainly haematological, with WHO grade III/IV leukocytopenia occurring in 5 patients. After a median follow-up of 19 months (range 10-45), all patients are alive: 22 are in ongoing remission, while 4 have relapsed between 12 and 19 months after treatment.

CONCLUSIONS

Our data demonstrate a high activity of R-CHOP/R-CNOP in relapsing MALT lymphoma irrespective of prior therapy.

Authors+Show Affiliations

Department of Internal Medicine I, University of Vienna, Vienna, Austria. markus.raderer@meduniwien.ac.atNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

17220639

Citation

Raderer, Markus, et al. "Activity of Rituximab Plus Cyclophosphamide, Doxorubicin/mitoxantrone, Vincristine and Prednisone in Patients With Relapsed MALT Lymphoma." Oncology, vol. 70, no. 6, 2006, pp. 411-7.
Raderer M, Wohrer S, Streubel B, et al. Activity of rituximab plus cyclophosphamide, doxorubicin/mitoxantrone, vincristine and prednisone in patients with relapsed MALT lymphoma. Oncology. 2006;70(6):411-7.
Raderer, M., Wohrer, S., Streubel, B., Drach, J., Jager, U., Turetschek, K., Troch, M., Puspok, A., Zielinski, C. C., & Chott, A. (2006). Activity of rituximab plus cyclophosphamide, doxorubicin/mitoxantrone, vincristine and prednisone in patients with relapsed MALT lymphoma. Oncology, 70(6), 411-7.
Raderer M, et al. Activity of Rituximab Plus Cyclophosphamide, Doxorubicin/mitoxantrone, Vincristine and Prednisone in Patients With Relapsed MALT Lymphoma. Oncology. 2006;70(6):411-7. PubMed PMID: 17220639.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Activity of rituximab plus cyclophosphamide, doxorubicin/mitoxantrone, vincristine and prednisone in patients with relapsed MALT lymphoma. AU - Raderer,Markus, AU - Wohrer,Stefan, AU - Streubel,Berthold, AU - Drach,Johannes, AU - Jager,Ulrich, AU - Turetschek,Karl, AU - Troch,Marlene, AU - Puspok,Andreas, AU - Zielinski,Christoph C, AU - Chott,Andreas, Y1 - 2007/01/12/ PY - 2006/05/29/received PY - 2006/10/14/accepted PY - 2007/1/16/pubmed PY - 2007/3/21/medline PY - 2007/1/16/entrez SP - 411 EP - 7 JF - Oncology JO - Oncology VL - 70 IS - 6 N2 - BACKGROUND: Various chemotherapeutic agents as well as the anti-CD20 antibody rituximab (R) have been tested in patients with mucosa-associated lymphoid tissue (MALT) lymphoma, but no standard chemotherapeutic regimen has emerged so far. Judging from the data obtained in various types of lymphoma, the activity of R appears to be enhanced by combination with chemotherapy. As no data on this topic exist for MALT lymphoma, we have retrospectively analysed our experience with R plus cyclophosphamide, doxorubicin/mitoxantrone, vincristine and prednisone (R-CHOP/R-CNOP) in patients with relapsed MALT lymphoma. PATIENTS AND METHODS: A total of 26 patients were identified, 15 were administered R-CHOP while 11 patients were given R-CNOP due to age >65 years or pre-existing cardiac conditions. Cycles were repeated every 21 days, and restaging was performed after 4 cycles of therapy. In case of complete remission, 2 further cycles were administered for consolidation while patients achieving partial remission or stable disease after restaging were given 4 further courses. RESULTS: A total of 170 cycles were administered to our patients (median 6, range 2-8). Twenty of the 26 patients (77%) achieved a complete remission and 6 (23%) a partial remission. Toxicities were mainly haematological, with WHO grade III/IV leukocytopenia occurring in 5 patients. After a median follow-up of 19 months (range 10-45), all patients are alive: 22 are in ongoing remission, while 4 have relapsed between 12 and 19 months after treatment. CONCLUSIONS: Our data demonstrate a high activity of R-CHOP/R-CNOP in relapsing MALT lymphoma irrespective of prior therapy. SN - 0030-2414 UR - https://www.unboundmedicine.com/medline/citation/17220639/Activity_of_rituximab_plus_cyclophosphamide_doxorubicin/mitoxantrone_vincristine_and_prednisone_in_patients_with_relapsed_MALT_lymphoma_ L2 - https://www.karger.com?DOI=10.1159/000098555 DB - PRIME DP - Unbound Medicine ER -